MX2018002821A - Derivados de fluoroindol como moduladores alostéricos positivos del receptor m1 muscarínico. - Google Patents
Derivados de fluoroindol como moduladores alostéricos positivos del receptor m1 muscarínico.Info
- Publication number
- MX2018002821A MX2018002821A MX2018002821A MX2018002821A MX2018002821A MX 2018002821 A MX2018002821 A MX 2018002821A MX 2018002821 A MX2018002821 A MX 2018002821A MX 2018002821 A MX2018002821 A MX 2018002821A MX 2018002821 A MX2018002821 A MX 2018002821A
- Authority
- MX
- Mexico
- Prior art keywords
- muscarinic
- positive allosteric
- allosteric modulators
- receptor positive
- compounds
- Prior art date
Links
- 102000007207 Muscarinic M1 Receptor Human genes 0.000 title abstract 3
- 108010008406 Muscarinic M1 Receptor Proteins 0.000 title abstract 3
- 230000003281 allosteric effect Effects 0.000 title abstract 2
- QISSVLCQDNIJCS-UHFFFAOYSA-N 2-fluoro-1h-indole Chemical class C1=CC=C2NC(F)=CC2=C1 QISSVLCQDNIJCS-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
La presente invención se relaciona con un compuesto de la fórmula (I), o con los estereoisómeros y sales farmacéuticamente aceptables como moduladores alostéricos positivos del receptor M1 muscarinico. Esta invención se relaciona también con métodos para hacer tales compuestos y con las composiciones farmacéuticas que comprenden tales compuestos. Los compuestos de esta invención son útiles en el tratamiento de varios trastornos que se relacionan con el receptor M1 muscarínico. (Fórmula I).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN4809CH2015 | 2015-09-10 | ||
| PCT/IB2016/054290 WO2017042643A1 (en) | 2015-09-10 | 2016-07-19 | Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018002821A true MX2018002821A (es) | 2018-09-12 |
| MX379454B MX379454B (es) | 2025-03-10 |
Family
ID=56618200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018002821A MX379454B (es) | 2015-09-10 | 2016-07-19 | Derivados de fluoroindol como moduladores alostéricos positivos del receptor m1 muscarínico. |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US10294217B2 (es) |
| EP (1) | EP3347349B1 (es) |
| JP (1) | JP6553811B2 (es) |
| KR (1) | KR102068237B1 (es) |
| CN (1) | CN108026073B (es) |
| AU (1) | AU2016320645B2 (es) |
| BR (1) | BR112018004719B1 (es) |
| CA (1) | CA2997956C (es) |
| CY (1) | CY1122321T1 (es) |
| DK (1) | DK3347349T3 (es) |
| EA (1) | EA033826B1 (es) |
| ES (1) | ES2750868T3 (es) |
| HR (1) | HRP20191869T1 (es) |
| HU (1) | HUE047056T2 (es) |
| IL (1) | IL257869A (es) |
| LT (1) | LT3347349T (es) |
| MA (1) | MA42769B1 (es) |
| MD (1) | MD3347349T2 (es) |
| ME (1) | ME03571B (es) |
| MX (1) | MX379454B (es) |
| NZ (1) | NZ740587A (es) |
| PL (1) | PL3347349T3 (es) |
| PT (1) | PT3347349T (es) |
| RS (1) | RS59473B1 (es) |
| SI (1) | SI3347349T1 (es) |
| SM (1) | SMT201900608T1 (es) |
| WO (1) | WO2017042643A1 (es) |
| ZA (1) | ZA201801463B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3697790B1 (en) | 2017-10-18 | 2023-01-18 | Suven Life Sciences Limited | Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators |
| MX2020004339A (es) * | 2017-10-27 | 2020-08-03 | Suven Life Sciences Ltd | Moduladores alostericos positivos del receptor m1 muscarinico. |
| BR112022015379A2 (pt) * | 2020-02-04 | 2022-09-27 | Mindset Pharma Inc | Derivados de 3-pirrolidino-indol como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc |
| EP4447953A1 (en) | 2021-12-13 | 2024-10-23 | Sage Therapeutics, Inc. | Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators |
| CN115385849B (zh) * | 2022-09-14 | 2024-01-26 | 南通瑞合达医药科技有限公司 | 一种N-Boc-3-氟-4-哌啶酮提纯的方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60123485A (ja) | 1983-12-08 | 1985-07-02 | Yoshitomi Pharmaceut Ind Ltd | インド−ル−３−カルボキサミド誘導体 |
| CA2399791A1 (en) | 2000-02-11 | 2001-08-16 | Bristol-Myers Squibb Company | Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases |
| DE602006015851D1 (de) | 2005-12-05 | 2010-09-09 | Merck Sharp & Dohme | Positive allosterische chinolon-m1-rezeptormodulatoren |
| BR112012003464B8 (pt) * | 2009-08-31 | 2021-05-25 | Merck Sharp & Dohme | compostos de piranil aril metil benzoquinaozlinona, uso dos mesmos, e, composição farmacêutica |
| NZ600674A (en) | 2009-12-17 | 2013-05-31 | Merck Sharp & Dohme | Quinoline amide m1 receptor positive allosteric modulators |
| US8883850B2 (en) | 2010-05-28 | 2014-11-11 | Merck Sharp & Dohme Corp. | Naphthalene carboxamide M1 receptor positive allosteric modulators |
| TW201512197A (zh) | 2013-08-30 | 2015-04-01 | Hoffmann La Roche | 吡咯并吡啶或吡唑并吡啶衍生物 |
| MX2016001942A (es) | 2013-09-27 | 2016-06-02 | Hoffmann La Roche | Derivados de indol e indazol. |
| GB201317363D0 (en) | 2013-10-01 | 2013-11-13 | Eisai Ltd | Novel compounds |
| WO2015080904A1 (en) | 2013-11-27 | 2015-06-04 | Vanderbilt University | Substituted 4-benzyl-3,4-dihydro-2h-benzo[b][1,4]oxazine-2carboxamide analogs as positive allosteric modulators of muscarinic acetycholine receptor m1 |
-
2016
- 2016-07-19 SI SI201630447T patent/SI3347349T1/sl unknown
- 2016-07-19 EP EP16750259.0A patent/EP3347349B1/en active Active
- 2016-07-19 CA CA2997956A patent/CA2997956C/en active Active
- 2016-07-19 LT LT16750259T patent/LT3347349T/lt unknown
- 2016-07-19 SM SM20190608T patent/SMT201900608T1/it unknown
- 2016-07-19 JP JP2018512868A patent/JP6553811B2/ja active Active
- 2016-07-19 CN CN201680052764.2A patent/CN108026073B/zh active Active
- 2016-07-19 RS RS20191328A patent/RS59473B1/sr unknown
- 2016-07-19 PT PT167502590T patent/PT3347349T/pt unknown
- 2016-07-19 AU AU2016320645A patent/AU2016320645B2/en active Active
- 2016-07-19 NZ NZ740587A patent/NZ740587A/en unknown
- 2016-07-19 MX MX2018002821A patent/MX379454B/es unknown
- 2016-07-19 MD MDE20180689 patent/MD3347349T2/ro unknown
- 2016-07-19 US US15/758,313 patent/US10294217B2/en active Active
- 2016-07-19 ES ES16750259T patent/ES2750868T3/es active Active
- 2016-07-19 PL PL16750259T patent/PL3347349T3/pl unknown
- 2016-07-19 HR HRP20191869TT patent/HRP20191869T1/hr unknown
- 2016-07-19 MA MA42769A patent/MA42769B1/fr unknown
- 2016-07-19 KR KR1020187009938A patent/KR102068237B1/ko active Active
- 2016-07-19 WO PCT/IB2016/054290 patent/WO2017042643A1/en not_active Ceased
- 2016-07-19 HU HUE16750259A patent/HUE047056T2/hu unknown
- 2016-07-19 ME MEP-2019-288A patent/ME03571B/me unknown
- 2016-07-19 DK DK16750259T patent/DK3347349T3/da active
- 2016-07-19 EA EA201890684A patent/EA033826B1/ru unknown
- 2016-07-19 BR BR112018004719-8A patent/BR112018004719B1/pt active IP Right Grant
-
2018
- 2018-03-02 ZA ZA2018/01463A patent/ZA201801463B/en unknown
- 2018-03-05 IL IL257869A patent/IL257869A/en active IP Right Grant
-
2019
- 2019-10-16 CY CY20191101086T patent/CY1122321T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SA518392101B1 (ar) | ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ | |
| MX390302B (es) | Oxiesteroles y metodos de uso de los mismos | |
| MX389592B (es) | Moduladores alostericos positivos del receptor m1 muscarinico | |
| MX2020010690A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| MD4800B1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
| PH12016501791B1 (en) | Muscarinic receptor agonists | |
| EA201891063A1 (ru) | Производные дигидроимидазопиразинона, применимые в лечении рака | |
| MX2016010056A (es) | 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso. | |
| NZ734400A (en) | Amide compounds as 5-ht4 receptor agonists | |
| NZ737892A (en) | Muscarinic m1 receptor positive allosteric modulators | |
| PH12017501876A1 (en) | Pyridopyrimidones and their use as nmda receptor modulators | |
| NZ740587A (en) | Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators | |
| MX2016009621A (es) | Derivados de fur0-3-carboxamida y metodos de uso. | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| EA201791480A1 (ru) | Новые производные бензимидазола в качестве антигистаминных агентов | |
| WO2015001541A3 (en) | Pharmaceutical film composition | |
| NZ763341A (en) | Polycyclic amides as muscarinic m1 receptor positive allosteric modulators | |
| NZ720879A (en) | Indazole compounds as 5-ht4 receptor agonists | |
| NZ764004A (en) | Heteroaryl compounds as muscarinic m1 receptor positive allosteric modulators | |
| PH12017501736B1 (en) | Indole derivatives | |
| MX2017002544A (es) | Derivados de isoquinolinona utiles en el tratamiento contra el cancer. | |
| TN2018000175A1 (en) | Indane derivatives as mglur7 modulators | |
| EA201600411A1 (ru) | Производные пиперидина для применения при лечении или профилактики психиатрических и неврологических состояний | |
| NZ764561A (en) | Substituted azacycles as muscarinic m1 receptor positive allosteric modulators |